Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 849-855

  George, B ^a   Kerridge, I ^a   Gilroy, N ^a   Huang, G ^a   Hertzberg, M ^a   Gottlieb, D ^a   Bradstock, K ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

CMV; Reactivation; RIC

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; DACLIZUMAB; ETANERCEPT; FLUDARABINE; FOSCARNET; GAMMAGARD SD; GANCICLOVIR; IMMUNOGLOBULIN G; INFLIXIMAB; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HERPES VIRUS INFECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; RISK FACTOR; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; VIRUS ACTIVATION; YOUNG ADULT;

EID: 77952423632     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.273     Document Type: Article

References (32)

1. Antin JH. Reduced intensity stem cell transplantation. Hematology Am Soc Hematol Educ Program 2007;2007:47-54.
2. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978-1985. (Pubitemid 34525478)
3. Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant 2003;32:695-701.
4. Hill QA, Hill A, Collyns TA, Pearce RM, Cook G. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:749-751.
5. Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E et al. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation. Ann Hematol 2003;82:621-627.
6. Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning. Bone Marrow Transplant 2007;40:137-143.
7. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Yang DH et al. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008;83:649-653.
8. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-4363.
9. Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004;33:839-846.
10. Nakai K, Kanda Y, Mineishi S, Saito T, Ohnishi M, Niiya H et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using antithymocyte globulin. Bone Marrow Transplant 2002;29:237-241.
11. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:707-714.
12. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V et al. Prophylactic infusion of cytomegalovirusspecific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008;112:3974-3981.
13. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004;6:171-178.
14. Oh SJ, Lee KH, Lee JH, Choi SJ, Kim WK, Lee JS et al. The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci 2004;19:172-176.
15. Nakamura R, Cortez K, Solomon S, Battiwala M, Gill VJ, Hensel N et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:235-242.
16. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307-310.
17. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005;36:797-802.
18. Busca A, Locatelli F, Barbui A, Ghisetti V, Cirillo D, Serra R et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2003;5:132-139. (Pubitemid 37356356)
19. Miller W, Flynn P, McCullough J, Balfour Jr HH, Goldman A, Haake R et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986;67:1162-1167.
20. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparellid E, Aschan J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78-83.
21. Moss P, Khan N. CD8 (+) T-cell immunity to cytomegalovirus. Hum Immunol 2004;65:456-464.
22. Kano Y, Shiohara T. Current understanding of cytomegalovirus infection in immunocompetent individuals. J Dermatol Sci 2000;22:196-204.
23. Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002;100:3690-3697.
24. Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007;39:293-299.
25. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008;93:248-256.
26. Ferrari V, Cacere CR, Machado CM, Pannuti CS, Dulley FL, Barros JC et al. Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation. Clin Immunol 2006;119:261-271.
27. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:3060-3067.
28. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-952. (Pubitemid 37211379)
29. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-2245.
30. Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001;113:1060-1071.
31. Winston DJ, Young JA, Pullarkat V, Papanicolau GA, Vij R, Vance E et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose-ranging study. Blood 2008;111:5403-5410.
32. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virusspecific T cells. Blood Cells Mol Dis 2008;40:63-67.